F. Hoffmann-La Roche AG announced on Monday that it entered into a definitive merger agreement to buy US company Carmot Therapeutics Inc. for $2.7 billion. Furthermore, Roche will pay up to $400 million to Carmot's shareholders based on the achievement of certain objectives.
"By combining Carmot’s portfolio with programs in our Pharmaceuticals pipeline and our Diagnostics expertise and portfolio of products across cardiovascular and metabolic diseases, we are aiming to improve the standard of care and positively impact patients’ lives," Roche's CEO Thomas Schinecker said.
The transaction is expected to close in the first quarter of 2024.
